Mirum Pharmaceuticals (MIRM) EBIAT (2020 - 2025)
Mirum Pharmaceuticals has reported EBIAT over the past 6 years, most recently at -$5.7 million for Q4 2025.
- Quarterly results put EBIAT at -$5.7 million for Q4 2025, up 75.91% from a year ago — trailing twelve months through Dec 2025 was -$23.4 million (up 73.43% YoY), and the annual figure for FY2025 was -$23.4 million, up 73.43%.
- EBIAT for Q4 2025 was -$5.7 million at Mirum Pharmaceuticals, down from $2.9 million in the prior quarter.
- Over the last five years, EBIAT for MIRM hit a ceiling of $57.5 million in Q4 2021 and a floor of -$74.0 million in Q2 2023.
- Median EBIAT over the past 5 years was -$26.1 million (2022), compared with a mean of -$24.7 million.
- Biggest five-year swings in EBIAT: soared 254.68% in 2021 and later tumbled 175.01% in 2023.
- Mirum Pharmaceuticals' EBIAT stood at $57.5 million in 2021, then tumbled by 163.31% to -$36.4 million in 2022, then rose by 2.12% to -$35.7 million in 2023, then soared by 33.28% to -$23.8 million in 2024, then skyrocketed by 75.91% to -$5.7 million in 2025.
- The last three reported values for EBIAT were -$5.7 million (Q4 2025), $2.9 million (Q3 2025), and -$5.9 million (Q2 2025) per Business Quant data.